Friday, September 2nd, Baltimore, MD - Insilico Medicine, Inc, one of the leading companies applying latest advances in artificial intelligence to drug discovery, biomarker development and aging research is co-organizing the 3rd International Practical Applications for Aging Research Forum at the Basel Life Science Week in Basel, Switzerland, September 21-22. On September 21st, the CEO of Insilico Medicine will present new data on geroprotectors, small molecules that mimic the young healthy state in old human tissues. The results are a result of a multi-year research program with multiple in silico predictions made using algorithms validated using data from many age-related diseases and culminated with in vitro validation. The manuscript presenting these research results was recently accepted by a major peer-reviewed journal "Aging" and will be published after the conference.
"Aging research is slowly gaining credibility and some of the largest pharmaceutical, biotechnology and nutritional companies are launching research programs to translate these new insights into products. For the third year in a row Insilico Medicine is co-organizing the Aging Forum during the Basel Life Science Week and bringing together world's top thought leaders in the field. This event intends to bridge academic and commercial research and foster collaborations that will result in practical solutions to one of humanity's most challenging problems", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine.
The BLSW conference is free to attend as it is sponsored by the city of Basel and large industry players headquartered in Basel including Novartis and Roche. The forum was originally organized by Alex Zhavoronkov of Insilico Medicine and Bhupinder Bhullar of Novartis and in 2016 it welcomed Brian Kennedy, the CEO of the Buck Institute on Aging as a co-organizer.
The 3rd annual forum will feature 20+ speakers from both the industry and academia and
Since its inception in 2014, scientists at Insilico Medicine are applying advanced signaling pathway analysis and deep learning techniques to analyze the changes transpiring in human tissues during aging and in many diseases and identifying molecules that may be able to correct the pathological processes in old tissues. In 2015 some of these predictions were validated experimentally and for the first time the results will be presented at the 3rd Annual International Aging Research for Drug Discovery Forum in Basel.
Other speakers representing companies and academic institutions working in longevity research will present their research findings including Michael West, CEO of Biotime, Robert Hariri, co-founder of Human Longevity, Mun Yew Wong, CEO of Asia Genomics, Jerome Feige, head of aging at Nestle, Vadim Gladyshev, professor at Harvard, Alexey Moskalev, professor of the Russian Academy of sciences, Jing-Dong Han of the Chinese Academy of Sciences, Zhaxybay Zhumadilov, director of the National Laboratory Astana, Miguel Camargo of UCB, Morten Scheibye-Knudsen of the Healthy Aging Center in Denmark, and many others.
In addition to Alex Zhavoronkov, who will present at the forum, five scientists from Insilico Medicine will present their posters on perspective geroprotectors, senolytic drugs and applications of deep learning to drug discovery and biomarker development.
"We are very excited to present our research at one of the largest drug discovery events in Europe and co-organize industry's first forum bridging advances in aging research with drug discovery for the third year in a row. Basel Life Science Week is expanding every year and should be on the calendar of every life sciences professional", said Alex Aliper, president of Insilico Medicine, Inc.
About Insilico Medicine
Insilico Medicine, Inc. is a bioinformatics company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore with R&D resources in Belgium, Russia, and Poland hiring talent through hackathons and competitions. It utilizes advances in genomics, big data analysis and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. The company pursues internal drug discovery programs in cancer, Parkinson's, Alzheimer's, sarcopenia and geroprotector discovery. Through its Pharmaceutical Artificial Intelligence division the company provides advanced machine learning services to biotechnology, pharmaceutical, and skin care companies. Brief company video: https:/